Business Context and Reporting Period
IN8bio, Inc. filed this Form 8-K on June 2, 2022, reporting the results of its annual meeting of stockholders held on June 1, 2022. The filing is a corporate-governance update and does not report financial results for a reporting period.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating and financial metrics.
Material Changes Versus the Prior Comparable Period
- Two director nominees, Emily Fairbairn and Luba Greenwood, were elected to serve until the 2025 annual meeting and until their successors are elected and qualified.
- Stockholders ratified the appointment of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, management commentary, contingencies, or unusual financial items. Broker non-votes were reported in the director elections; no broker non-votes were listed for the auditor ratification proposal.
Investor Verification Items
- Verify the voting results and share-count presentation in the definitive proxy statement filed April 22, 2022.
- Confirm the roles and terms of the elected directors.
- Confirm CohnReznick LLP’s appointment for the fiscal year ending December 31, 2022.
- Review subsequent filings for financial results, liquidity, financing activity, and clinical or corporate developments, which are not addressed in this Form 8-K.